#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14488	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2473	720.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1634	1634	C	936	C,T,G	934,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14488	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2473	720.0	0	HET	.	.	.	G1158A,T	.	1158	1158	G	1608	1608	G	882	G,A,T	685,195,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	742.1	0	.	n	.	0	T695C	SNP	695	695	T	1223	1223	C	845	C,T,G,A	842,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	742.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1865	1865	A	1030	A,C	1029,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	742.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2499	2499	C	828	C,T,A	825,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	742.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3125	3125	T	875	T,C,G	673,201,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	742.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2573	2573	A	777	A	777	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	742.1	0	HET	.	.	.	G2872A,T	.	2872	2872	G	3400	3400	G	956	G,A,T	502,453,1	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2274	folP	852	852	100.0	folP.l15.c4.ctg.1	1996	141.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1186	1188	AGC	235;239;237	A,G,C;G,A;C,G	233,1,1;237,2;236,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5690	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3711	190.4	1	SNP	p	S91F	0	.	.	271	273	TCC	729	731	TCC	212;215;217	T;C;C	212;215;217	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5690	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3711	190.4	1	SNP	p	D95N	0	.	.	283	285	GAC	741	743	GAC	208;208;209	G;A,C;C	208;207,1;209	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5690	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3711	190.4	1	SNP	p	D95G	0	.	.	283	285	GAC	741	743	GAC	208;208;209	G;A,C;C	208;207,1;209	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	2052	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1824	139.7	1	SNP	p	G45D	1	.	.	133	135	GAC	711	713	GAC	257;254;257	G;A,C;C	257;253,1;257	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1212	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	1304	115.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5340	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3483	190.8	1	SNP	p	D86N	0	.	.	256	258	GAC	792	794	GAC	236;238;237	G;A,C;C	236;237,1;237	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5340	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3483	190.8	1	SNP	p	S87I	0	.	.	259	261	AGT	795	797	AGT	237;240;240	A,C;G,C;T,G	236,1;239,1;239,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5340	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3483	190.8	1	SNP	p	S87R	0	.	.	259	261	AGT	795	797	AGT	237;240;240	A,C;G,C;T,G	236,1;239,1;239,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5340	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3483	190.8	1	SNP	p	S87W	0	.	.	259	261	AGT	795	797	AGT	237;240;240	A,C;G,C;T,G	236,1;239,1;239,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5340	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3483	190.8	1	SNP	p	S88P	0	.	.	262	264	TCC	798	800	TCC	245;244;247	T,G;C,T,A;C,A	244,1;242,1,1;246,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4486	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3136	178.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1788	1790	GGC	261;257;252	G,A;G;C,G	260,1;257;250,2	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4080	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2827	179.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1484	1486	GCA	225;223;224	G,C;C;A	224,1;223;224	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4080	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2827	179.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1487	1489	ATC	225;222;222	A,C;T;C,A	224,1;222;221,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4080	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2827	179.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1499	1501	GTG	213;209;208	G;T;G,T	213;209;207,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4080	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2827	179.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1499	1501	GTG	213;209;208	G;T;G,T	213;209;207,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4080	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2827	179.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2003	2005	ACC	248;248;246	A;C,G;C	248;247,1;246	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4080	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2827	179.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2057	2059	GCG	237;238;237	G;C;G,A	237;238;236,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4080	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2827	179.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2057	2059	GCG	237;238;237	G;C;G,A	237;238;236,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4080	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2827	179.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2180	2182	GGC	226;225;227	G;G;C	226;225;227	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4080	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2827	179.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2189	2191	GGC	233;233;235	G;G;C	233;233;235	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4080	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2827	179.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2207	2209	CCG	222;224;224	C,G,A;C;G,C	220,1,1;224;221,3	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5560	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3428	202.1	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1814	1816	CTG	243;246;245	C;T,G;G,T	243;245,1;244,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2596	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2256	143.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	759	759	C	189	C	189	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	615	617	GGA	231;232;231	G;G;A	231;232;231	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	V75I	NONSYN	223	225	GTT	696	698	ATT	243;245;246	A;T;T,C	242;244;243,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	738	740	AGC	250;250;249	A,C;G;C,G	248,1;249;247,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	V98I	NONSYN	292	294	GTC	765	767	ATC	220;219;219	A;T,G;C	220;218,1;219	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	.	MULTIPLE	358	359	AA	830	831	CG	180;176	C;G,A	180;175,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	.	MULTIPLE	361	362	GA	833	835	CAG	174;174;175	C,T,A;A,G,C;G,C	172,1,1;172,1,1;173,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	N122K	NONSYN	364	366	AAC	837	839	AAA	170;170;171	A,C;A;A,C	169,1;170;170,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	864	866	TAT	179;178;179	T;A;T,G	179;178;177,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	N134E	NONSYN	400	402	AAT	873	875	GAG	173;173;176	G,T;A;G	172,1;173;176	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	V135L	NONSYN	403	405	GTG	876	878	CTT	177;179;179	C,T;T,C,G;T	176,1;177,1,1;179	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	G140K	NONSYN	418	420	GGA	891	893	AAA	184;183;182	A;A,C;A	184;182,1;182	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	K143E	NONSYN	427	429	AAA	900	902	GAA	190;189;190	G,A,T;A,G;A,T	188,1,1;187,2;189,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	924	926	GCA	197;196;197	G,C;C;A	196,1;196;197	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1110	1112	TCA	273;273;276	T;C,A;A	273;272,1;276	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1230	1232	CAA	186;177;174	C,G,T;A;A	184,1,1;177;174	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	.	INDELS	760	761	AC	1234	1237	ATCG	175;175;172;167	A,G;T,G;C;G	174,1;173,2;172;167	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	.	INDELS	763	764	TG	1240	1243	TAGT	166;166;164;164	T;A;G;T	166;166;164;164	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1248	1250	GAT	168;169;169	G;A;T	168;169;169	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1356	1358	AGT	216;219;218	A,C;G;T	215,1;219;218	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1362	1364	GAC	220;220;221	G;A;C,A	220;220;220,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1365	1367	TAC	222;222;222	T;A;C	222;222;222	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	1	SNP	p	G120K	1	.	.	358	360	AAG	830	832	CGG	180;176;175	C;G,A;G,C	180;175,1;174,1	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	1	SNP	p	A121D	1	.	.	361	363	GAC	833	836	CGC	174;175;172	C,T,A;G,C;C,A	172,1,1;173,2;171,1	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2634	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1776	183.5	1	SNP	p	D121N	0	.	.	361	363	GAC	833	836	CGC	174;175;172	C,T,A;G,C;C,A	172,1,1;173,2;171,1	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10008	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5357	232.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2269	2271	AAT	272;273;275	A,G;A,T;T,G	271,1;272,1;274,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1520	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1618	117.4	1	SNP	p	V57M	1	.	.	169	171	ATG	812	814	ATG	284;282;281	A;T,G;G	284;281,1;281	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
